WO2011073905A8 - Novel tumor markers - Google Patents
Novel tumor markers Download PDFInfo
- Publication number
- WO2011073905A8 WO2011073905A8 PCT/IB2010/055805 IB2010055805W WO2011073905A8 WO 2011073905 A8 WO2011073905 A8 WO 2011073905A8 IB 2010055805 W IB2010055805 W IB 2010055805W WO 2011073905 A8 WO2011073905 A8 WO 2011073905A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stage
- progressed
- cancer
- tumor markers
- progression
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a tumor marker or group of tumor markers associated with the progression of a cancer disease from a less progressed stage to a more progressed stage, wherein the expression of the tumor markers is modified when comparing the expression in the less progressed stage and in the more progressed stage. The present invention further relates to a composition for diagnosing, detecting, graduating, monitoring or prognosticating a cancer disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage comprising affinity ligands for the expression products of the tumor markers, to corresponding methods, and to the use of said tumor markers for detecting, diagnosing,graduating, monitoring or prognosticating a cancer disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage. The present invention further relates to a corresponding immunoassay, to a method of identifying an individual for eligibility for a cancer disease therapy, as well as to a pharmaceutical composition based on the inhibition of the expression of said tumor markers. The present invention further relates to a corresponding immunoassay for stratifying a patient or cohort of patients with a cancer disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage to a therapeutic treatment for monitoring a therapeutic treatment of the stratified patient(s) during the progression from a less progressed cancer stage to a more progressed cancer stage.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09179125.1 | 2009-12-14 | ||
EP09179125A EP2295977A1 (en) | 2009-09-03 | 2009-12-14 | Novel tumor markers |
EP10155369 | 2010-03-03 | ||
EP10155369.1 | 2010-03-03 | ||
EP10165039.8 | 2010-06-07 | ||
EP10165039 | 2010-06-07 | ||
PCT/IB2010/055796 WO2011073896A1 (en) | 2009-12-14 | 2010-12-14 | Novel tumor markers |
IBPCT/IB2010/055796 | 2010-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011073905A1 WO2011073905A1 (en) | 2011-06-23 |
WO2011073905A8 true WO2011073905A8 (en) | 2011-12-08 |
Family
ID=44246840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/055805 WO2011073905A1 (en) | 2009-12-14 | 2010-12-14 | Novel tumor markers |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011073905A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013182537A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Autoimmune antibodies |
EP3102944B1 (en) * | 2014-02-04 | 2018-10-10 | CellTrend GmbH | Diagnosis of cancer by detecting auto-antibodies against egf-receptor |
GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
WO2019139754A2 (en) * | 2017-12-19 | 2019-07-18 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for fetal growth |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090580A1 (en) * | 2001-05-03 | 2002-11-14 | National Cancer Centre Of Singapore Pte Ltd | Identifying liver cancer by detecting aberrant expression of insulin like growth factor binding protein |
AU2003298689A1 (en) * | 2002-11-21 | 2004-06-18 | Wyeth | Methods for diagnosing rcc and other solid tumors |
AU2003298786A1 (en) * | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
-
2010
- 2010-12-14 WO PCT/IB2010/055805 patent/WO2011073905A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2011073905A1 (en) | 2011-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011027310A8 (en) | Novel tumor markers | |
WO2011027308A8 (en) | Novel tumor markers | |
WO2006036220A3 (en) | Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
CY1118566T1 (en) | DIAGNOSIS USING INTERFERENCE TYPE 1 | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
WO2007140958A3 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
WO2009037454A3 (en) | Cancer marker and therapeutic target | |
WO2008072777A3 (en) | Ttk as tumor marker and therapeutic target for lung cancer | |
MX2023001945A (en) | Compositions and methods for screening solid tumors. | |
EP2527466A3 (en) | Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
NZ592241A (en) | Ykl-40 as a marker for gastrointestinal cancers | |
MX2012014739A (en) | Novel antibody for the diagnosis and/or prognosis of cancer. | |
BR112016007864A2 (en) | Method for cancer prognosis and metastasis treatment | |
WO2005085860A3 (en) | New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis | |
WO2011153545A3 (en) | Gene expression signature as a predictor of chemotherapeutic response in breast cancer | |
WO2011133770A3 (en) | Salivary protein markers for detection of breast cancer | |
WO2008088860A3 (en) | Polymorphisms in the egfr pathway as markers for cancer treatment | |
WO2013096903A3 (en) | Methods for prediction of clinical response to radiation therapy in cancer patients | |
WO2011073905A8 (en) | Novel tumor markers | |
WO2012116229A3 (en) | Compositions and methods for personal tumor profiling treatment | |
WO2012044696A3 (en) | Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature | |
WO2011027311A3 (en) | Novel tumor markers | |
WO2010131193A8 (en) | Phosphodiesterase 9a as prostate cancer marker | |
SG179129A1 (en) | Method for identifying whether a patient will be responder or not to immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10809189 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10809189 Country of ref document: EP Kind code of ref document: A1 |